A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
BACKGROUND AND OBJECTIVE: Two long-acting depot somatostatin analogues have recently been licensed for the treatment of acromegaly. We wished to assess the effectiveness of both these drugs in suppressing mean GH to a target of < 5 mU/l in patients with acromegaly unselected for responsivenes...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1999
|
| _version_ | 1826306593684193280 |
|---|---|
| author | Turner, H Vadivale, A Keenan, J Wass, J |
| author_facet | Turner, H Vadivale, A Keenan, J Wass, J |
| author_sort | Turner, H |
| collection | OXFORD |
| description | BACKGROUND AND OBJECTIVE: Two long-acting depot somatostatin analogues have recently been licensed for the treatment of acromegaly. We wished to assess the effectiveness of both these drugs in suppressing mean GH to a target of < 5 mU/l in patients with acromegaly unselected for responsiveness to octreotide, and also to compare the effects of both drugs METHODS: We prospectively studied 10 unselected patients with acromegaly who were treated first with lanreotide (LAN) and then octreotide LAR (LAR) following a washout period. The target for therapy was to achieve mean GH less than 5 mU/l. RESULTS: Five (50%) patients achieved mean GH < 5 mU/l on lanreotide 30 mg every 10 days, and 7 out of 9 (77.8%) achieved this level when the dose frequency was increased to every 7 days. On 20 mg octreotide LAR, 6 (60%) patients achieved the target mean GH and a further 2 (80%) when the dose was increased to 30 mg. Normalization of IGF-1 occurred in 5/9 (55.6%) patients who received lanreotide and 7/10 (70%) of those who received octreotide LAR. There was a significant difference in mean GH attained on the 2 drugs. The patients' mean GH was significantly lower when treated with octreotide LAR 20 mg every 4 weeks compared with lanreotide 30 mg every 10 days (P = 0.037). Maximal suppression of mean GH with 30 mg octreotide LAR or 7 day dosing of lanreotide was significantly greater on octreotide LAR (P < 0.02). CONCLUSIONS: At current dose recommendations, lanreotide and octreotide LAR are both effective in lowering mean GH to 'safe' (< 5 mU/l) levels in 80% patients but octreotide LAR treatment leads to significantly lower mean GH. |
| first_indexed | 2024-03-07T06:50:18Z |
| format | Journal article |
| id | oxford-uuid:fc568980-978a-4e96-bf4e-c21d48b74404 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:50:18Z |
| publishDate | 1999 |
| record_format | dspace |
| spelling | oxford-uuid:fc568980-978a-4e96-bf4e-c21d48b744042022-03-27T13:19:56ZA comparison of lanreotide and octreotide LAR for treatment of acromegaly.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fc568980-978a-4e96-bf4e-c21d48b74404EnglishSymplectic Elements at Oxford1999Turner, HVadivale, AKeenan, JWass, JBACKGROUND AND OBJECTIVE: Two long-acting depot somatostatin analogues have recently been licensed for the treatment of acromegaly. We wished to assess the effectiveness of both these drugs in suppressing mean GH to a target of < 5 mU/l in patients with acromegaly unselected for responsiveness to octreotide, and also to compare the effects of both drugs METHODS: We prospectively studied 10 unselected patients with acromegaly who were treated first with lanreotide (LAN) and then octreotide LAR (LAR) following a washout period. The target for therapy was to achieve mean GH less than 5 mU/l. RESULTS: Five (50%) patients achieved mean GH < 5 mU/l on lanreotide 30 mg every 10 days, and 7 out of 9 (77.8%) achieved this level when the dose frequency was increased to every 7 days. On 20 mg octreotide LAR, 6 (60%) patients achieved the target mean GH and a further 2 (80%) when the dose was increased to 30 mg. Normalization of IGF-1 occurred in 5/9 (55.6%) patients who received lanreotide and 7/10 (70%) of those who received octreotide LAR. There was a significant difference in mean GH attained on the 2 drugs. The patients' mean GH was significantly lower when treated with octreotide LAR 20 mg every 4 weeks compared with lanreotide 30 mg every 10 days (P = 0.037). Maximal suppression of mean GH with 30 mg octreotide LAR or 7 day dosing of lanreotide was significantly greater on octreotide LAR (P < 0.02). CONCLUSIONS: At current dose recommendations, lanreotide and octreotide LAR are both effective in lowering mean GH to 'safe' (< 5 mU/l) levels in 80% patients but octreotide LAR treatment leads to significantly lower mean GH. |
| spellingShingle | Turner, H Vadivale, A Keenan, J Wass, J A comparison of lanreotide and octreotide LAR for treatment of acromegaly. |
| title | A comparison of lanreotide and octreotide LAR for treatment of acromegaly. |
| title_full | A comparison of lanreotide and octreotide LAR for treatment of acromegaly. |
| title_fullStr | A comparison of lanreotide and octreotide LAR for treatment of acromegaly. |
| title_full_unstemmed | A comparison of lanreotide and octreotide LAR for treatment of acromegaly. |
| title_short | A comparison of lanreotide and octreotide LAR for treatment of acromegaly. |
| title_sort | comparison of lanreotide and octreotide lar for treatment of acromegaly |
| work_keys_str_mv | AT turnerh acomparisonoflanreotideandoctreotidelarfortreatmentofacromegaly AT vadivalea acomparisonoflanreotideandoctreotidelarfortreatmentofacromegaly AT keenanj acomparisonoflanreotideandoctreotidelarfortreatmentofacromegaly AT wassj acomparisonoflanreotideandoctreotidelarfortreatmentofacromegaly AT turnerh comparisonoflanreotideandoctreotidelarfortreatmentofacromegaly AT vadivalea comparisonoflanreotideandoctreotidelarfortreatmentofacromegaly AT keenanj comparisonoflanreotideandoctreotidelarfortreatmentofacromegaly AT wassj comparisonoflanreotideandoctreotidelarfortreatmentofacromegaly |